Table 3:
Factors influencing inter-platform correlation and biomarker-AKI association discrepancies
| Factors | Inter-platform Correlation | Biomarker-AKI Association Discrepancy | Results |
|---|---|---|---|
| Biomarker concentration (among samples within a biomarker, and across biomarkers) | Strong | Unclear beyond rs:OR relationship | Figures 2 and 3, Supplemental Figure 1 |
| Immunoassay type | Weak; more research needed | None; more research needed | Supplemental Figure 2 |
| SomaScan inter-assay %CV | None-to-weak | None | Supplemental Figure 3 |
| Immunoassay inter-assay %CV | None | None | Supplemental Figure 3 |
| Immunoassay intra-assay %CV | None | None | Supplemental Figure 4 |
| Target molecular weight | None | None | Supplemental Figure 5 |
| Target basal pI | None | None | Supplemental Figure 6 |
| Storage time | None | - | Supplemental Figure 7 |
| Aptamer cross-reactivity with homologous proteinsA | None; more research needed | Low-correlation cross-reactive were more concordant; more research needed | Supplemental Figure 8 |
| Aptamer orthogonal validation by mass spectrometryB | Some; more research needed (sparse) | - | cystatin C, CK-MB, Gal3, hFABP, bFGF |
| Aptamer orthogonal validation by cis-pQTLB | Weak; more research needed | None | BNP-32, NT-proBNP, CK-MKB, CST3, PlGF, VEGFc, VEGF, Tie2, Kim-1, YKL-40, Gal3, ST2, and TNF-R2 |